BioCardia works with regenerative medicine to engineer treatments for cardiovascular diseases. The two products that its scientists are researching are CardiAMP™, which is a cell therapy system developed by using patients’ own cells from the bone marrow. This is expected to treat post-heart attack heart failure or chronic myocardial ischemia, which reduces the heart's ability to pump blood. Its second cell therapy system is CardiALLO™, which also uses bone marrow cells or CAR-T to treat heart and lung related diseases. Cardiac cell therapy is performed with direct or indirect regeneration.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.